Table 2.
Outflow facility in monkeys after topical and/or intracameral 1,25-(OH)2D3
| Outflow facility (μl/min/mmHg) | |||
|---|---|---|---|
| Treated | Control | Treated/Control | |
| A. 1 μg Intracameral (n=4) | |||
| Baseline | 0.24 ± 0.08 | 0.29 ± 0.07 | 0.90 ± 0.34 |
| 1,25-(OH)2D3 | 0.37 ± 0.07 | 0.47 ± 0.05 | 0.82 ± 0.20 |
| 1,25-(OH)2D3/BL | 1.80 ± 0.30 | 1.79 ± 0.30 | 1.04 ± 0.13 |
| B. 5 μg Topical (bid, 4 treatments); 1 μg Intracameral (n=4) | Treated | Control | Treated/Control |
| Baseline | 0.31 ± 0.12 | 0.38 ± 0.23 | 1.11 ± 0.17 |
| 1,25-(OH)2D3 | 0.51 ± 0.26 | 0.68 ± 0.43 | 0.91 ± 0.27 |
| 1,25-(OH)2D3/BL | 1.38 ± 0.23 | 1.74 ± 0.20 | 0.84 ± 0.18 |
| Combined data from A and B (n=8) | Treated | Control | Treated/Control |
| Baseline | 0.28 ± 0.07 | 0.34 ± 0.11 | 1.00 ± 0.18 |
| 1,25-(OH)2D3 | 0.44 ± 0.13 | 0.58 ± 0.20 | 0.87 ± 0.16 |
| 1,25-(OH)2D3/BL | 1.59 ± 0.19* | 1.77 ± 0.16* | 0.94 ± 0.11 |
| C. 1 μl intracameral propylene glycol (n=5) | Treated | Control | Treated/Control |
| Baseline | 0.34 ± 0.04 | 0.47 ± 0.11 | 0.90 ± 0.28 |
| Propylene Glycol | 0.34 ± 0.06 | 0.49 ± 0.10 | 0.72 ± 0.06* |
| PropGly/BL | 1.03 ± 0.18 | 1.09 ± 0.17 | 1.03 ± 0.18 |
| D. 5 μg topical VitD (5–7 treatments) with nasolacrimal duct occlusion (n=8) | Treated | Control | Treated/Control |
| Baseline | 0.38 ± 0.05 | 0.45 ± 0.04 | 0.85 ± 0.10 |
| 1,25-(OH)2D3 | 0.45 ± 0.05 | 0.46 ± 0.06 | 1.03 ± 0.10 |
| 1,25-(OH)2D3/BL | 1.25 ± 0.12 | 1.05 ± 0.14 | 1.35 ± 0.24 |
Data are mean ± sem. Outflow facility units are μl/min/mmHg; ratios are unitless. BL, baseline. A. Following baseline measurements, intracameral 1,25-(OH)2D3 was administered to one eye; propylene vehicle (1 μl) to the contralateral control eye. Outflow facility measurements post treatment were begun 75 min after 1,25-(OH)2D3 administration and continued for 90 min. B. Topical administration bid for 2 days (4 treatments) with intracameral treatment on the 3rd day as for A. C. Intracameral bolus injection of 1 μl propylene glycol to one eye, Barany’s perfusand to the contralateral control eye. Outflow facility measurements were begun 75 min post treatment and continued for 90 min. D. Outflow facility was measured on day 3 or 4 following twice daily treatment with 5 μg 1,25-(OH)2D3 to one eye or 5 μl propylene glycol to the contralateral control eye. The nasolacrimal duct was occluded for 2 min following each administration which resulted in a unilateral IOP reduction. Outflow facility was measured for 2 h during the interval 2–4 h after the 5th or 7th treatment. Baseline was measured on a separate day.
No significant difference was found between eyes after correction for baseline when the data for the entire 90–120 min period were analyzed or when 30 min increments were analyzed (not shown). Significantly different from 1.0 by the two-tailed paired t-test:
p<0.05